Envision Optics Llc | |
2105 Interstate Dr, Opelika, AL 36801-1526 | |
(956) 335-6476 | |
Not Available |
Full Name | Envision Optics Llc |
---|---|
Type | Facility |
Speciality | Eyewear Supplier |
Location | 2105 Interstate Dr, Opelika, Alabama |
Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1770225930 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
152W00000X | Optometrist | (* (Not Available)) | Secondary |
332H00000X | Eyewear Supplier | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Envision Optics Llc 1943 Pleasant Hill Rd, Duluth, GA 30096-4625 Ph: () - | Envision Optics Llc 2105 Interstate Dr, Opelika, AL 36801-1526 Ph: (956) 335-6476 |
News Archive
Sending general practitioners (GPs) in England a letter giving feedback on their antibiotic prescribing habits could cut unnecessary prescriptions of antibiotics, according to the first nationwide randomised trial of its kind involving over 1500 GP practices, published in The Lancet.
The U.S. Food and Drug Administration announced today that it has approved the 2012-2013 influenza (flu) vaccine formulation for all six manufacturers licensed to produce and distribute the vaccines in the United States.
A new study published in The BMJ in April 2020 suggests that almost any remedial diet can result in a certain amount of weight loss and a better cardiovascular risk profile over the next six months, compared with the usual diet. However, at the 12-month mark, the dieter has mostly gained back the weight, while most cardiovascular risk factors are back at their original levels.
Pharmaceutical manufacturer Schering Plough will reimburse Washington's Medicaid program $3.57 million in a nationwide settlement of allegations the drug maker failed to offer state Medicaid programs its best price for the popular antihistamine drug Claritin.
A first-ever interlaboratory study of four versions of a therapeutic protein drug—all manufactured from living cells—reports that an established analytical tool akin to magnetic resonance imaging reliably assessed the atomic structures of the biologically similar products, yielding the equivalent of a fingerprint for each.
› Verified 2 days ago